Stockreport

ONO PHARMA Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL [Yahoo! Finance]

ONO PHARM CO UNSP/ADR  (OPHLY) 
NASDAQ:AMEX Investor Relations: ono.co.jp/eng/investor/index.html
PDF OSAKA, Japan March 21, 2024 /PRNewswire/ -- ONO Pharmaceuticals, Co., Ltd. today announced it has completed target patient enrollment of the first arm (Part A) of the P [Read more]